Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
161.50    -11.00 (-6.38%)
Bid:
158.50
Ask:
162.50
Spread: 4.00 (2.524%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Blocklisting Six Monthly Return

29 Jun 2015 07:00

RNS Number : 4650R
Hutchison China Meditech Limited
29 June 2015
 

 

 

 

Blocklisting Six Monthly Return

 

 

London: Monday, 29 June 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) announces the following blocklisting six monthly return:

 

1.

Name of applicant:

 

Hutchison China MediTech Limited

2.

Name of scheme:

 

Hutchison China MediTech Limited Share Option Scheme

 

3.

Period of return:

 

From 29 December 2014 to 28 June 2015

4.

Balance under scheme from previous return:

 

696,051 ordinary shares of US$1 each

 

5.

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

 

Nil

6.

Number of securities issued/allotted under scheme during period:

223,288 ordinary shares of US$1 each

7.

Balance under scheme not yet issued/allotted at end of the period:

 

472,763 ordinary shares of US$1 each

8.

Number and class of securities originally listed and the date of admission:

 

2,560,606 ordinary shares of US$1 each admitted on 26 June 2007

9.

Total number of securities in issue at the end of the period:

53,299,964 ordinary shares of US$1 each

Name of contact:

 

Christian Hogg

Address of contact:

 

21/F., Hutchison House, 10 Harcourt Road, Hong Kong

 

Telephone number of contact:

 

+852 2121 8200

 

 

Ends

 

 

Enquiries

 

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

 

Panmure Gordon (UK) Limited

Telephone: +44 20 7886 2500

Richard Gray

Andrew Potts

 

 

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 20 7638 9571

Mobile: +44 7973 611 888

Mobile: +44 7967 566 919

 

About Chi-Med

 

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK:1). For more information, please visit: www.chi-med.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRUKSVRVWANURR
Date   Source Headline
31st Dec 20207:00 amRNSTotal Voting Rights
30th Dec 202012:00 pmRNSNMPA approval of Surufatinib in China for ep-NET
29th Dec 20207:45 amRNSUS NDA Rolling Submission of Surufatinib Initiated
22nd Dec 20207:00 amRNSChi-Med to Present at JPM
15th Dec 20209:45 amRNSGrant of Share Options under Share Option Scheme
30th Nov 20207:00 amRNSTotal Voting Rights
27th Nov 20207:00 amRNSNotification of Dilution of Voting Rights
17th Nov 20207:00 amRNSUS$100m Equity Investment by CPP Investments
5th Nov 20209:00 amRNSChi-Med to Present HMPL-689 Clinical Data at ASH
30th Oct 202012:00 pmRNSChi-Med to Attend Upcoming Conferences
30th Oct 20207:00 amRNSTotal Voting Rights
30th Sep 20207:00 amRNSTotal Voting Rights
21st Sep 20207:00 amRNSSurufatinib Data at ESMO and in Lancet Oncology
17th Sep 202011:45 amRNSSecond Chinese NDA Acceptance for Surufatinib
4th Sep 20207:00 amRNSChi-Med Initiates Global Phase III Trial
3rd Sep 20207:00 amRNSChi-Med Initiates a Phase II Trial
28th Aug 202011:30 amRNSTotal Voting Rights
24th Aug 20207:00 amRNSClinical Data to be Presented at ESMO 2020
12th Aug 202010:30 amRNSGrant of Share Options under Share Option Scheme
10th Aug 20207:00 amRNSSurufatinib Marketing Authorization Application
30th Jul 202012:00 pmRNSInterim Results and Clinical Update
30th Jul 20207:00 amRNSBlock Admission Application
28th Jul 20207:00 amRNSChi-Med & Lilly Collaborate on Elunate in China
28th Jul 20207:00 amRNSSavolitinib NDA Granted Priority Review in China
24th Jul 20207:00 amRNSChi-Med Initiates HMPL-306 Phase I Trial in China
8th Jul 20208:00 amRNSHolding(s) in Company
7th Jul 20208:00 amRNSHolding(s) in Company
7th Jul 20207:00 amRNSNotification of Dilution of Voting Rights
29th Jun 20207:00 amRNSBlocklisting Six Monthly Return
26th Jun 20207:00 amRNSNotice of Results
25th Jun 20207:15 amRNS$100 Million Equity Investment by General Atlantic
18th Jun 20208:15 amRNSFruquintinib Granted US FDA Fast Track Designation
9th Jun 20207:00 amRNSUS$95m Guangzhou Land Compensation Agreement
4th Jun 20207:00 amRNSContinuation of Phase III FRUTIGA Study
2nd Jun 20204:40 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:37 pmRNSPrice Monitoring Extension
1st Jun 20207:00 amRNSChi-Med Plans to Submit US NDA for Surufatinib
29th May 20201:00 pmRNSChi-Med to Discuss Data Presented at ASCO20
29th May 20207:00 amRNSNDA Acceptance in China for Savolitinib
26th May 20207:00 amRNSChi-Med and BeiGene Enter Clinical Collaboration
14th May 20207:00 amRNSClinical Data to be Presented at ASCO20
11th May 20204:41 pmRNSSecond Price Monitoring Extn
11th May 20204:36 pmRNSPrice Monitoring Extension
11th May 20207:00 amRNSChi-Med to Attend Upcoming Investor Conferences
29th Apr 202011:45 amRNSGrant of Share Options under Share Option Scheme
27th Apr 20202:00 pmRNSResult of AGM
22nd Apr 20209:00 amRNSVirtual Presentations of Surufatinib at AACR
21st Apr 202011:30 amRNSGrant of LTIP Awards and Share Options
17th Apr 20207:00 amRNSSurufatinib Granted FDA Fast Track Designations
31st Mar 20207:04 amRNSChina Phase II trial initiation in mesothelioma

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.